[{"indications": "Indications\u00a0treatment and prevention of postmenopausal osteoporosis", "name": "RALOXIFENE HYDROCHLORIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.1 Female sex hormones", "6.4.1.1 Oestrogens and HRT", "Raloxifene", "RALOXIFENE HYDROCHLORIDE"], "cautions": "Cautions\u00a0risk factors for venous thromboembolism\r\n(discontinue if prolonged immobilisation); risk factors for stroke; breast cancer (\n(From Raloxifene: British National Formulary)\nRaloxifene); history of oestrogen-induced\r\nhypertriglyceridaemia (monitor serum triglycerides);\r\navoid in acute porphyria (%s\n(From 9.8.2 Acute porphyrias: British National Formulary)\n9.8.2 Acute porphyrias); interactions: Appendix 1 (raloxifene)", "side-effects": "Side-effects\u00a0hot flushes, leg cramps, peripheral oedema, influenza-like\r\nsymptoms; less commonly venous thromboembolism, thrombophlebitis; rarely rashes, gastro-intestinal disturbances, hypertension,\r\narterial thromboembolism, headache (including migraine), breast discomfort,\r\nthrombocytopenia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/73962.htm", "doses": ["60\u00a0mg once daily"]}]